Holen Sie sich die Stockscreener-App
7.72
0.39%
-0.03
Handel nachbörslich:
7.87
0.15
+1.94%
Schlusskurs vom Vortag:
$7.75
Offen:
$7.87
24-Stunden-Volumen:
1.11M
Relative Volume:
1.40
Marktkapitalisierung:
$550.61M
Einnahmen:
$133.62M
Nettoeinkommen (Verlust:
$-177.37M
KGV:
-2.6713
EPS:
-2.89
Netto-Cashflow:
$23.50M
1W Leistung:
+3.07%
1M Leistung:
-12.57%
6M Leistung:
-52.61%
1J Leistung:
-51.66%
1-Tages-Spanne:
$7.675
$8.24
1-Wochen-Bereich:
$6.92
$8.24
52-Wochen-Spanne:
$6.92
$27.24
Xencor Inc Stock (XNCR) Company Profile
Firmenname
Xencor Inc
Sektor
Branche
Telefon
626-305-5900
Adresse
465 N. HALSTEAD ST., PASADENA, CA
Vergleichen Sie XNCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
7.72 | 552.75M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2024-12-12 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | Bestätigt | BTIG Research | Buy |
| 2024-02-28 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Eingeleitet | BofA Securities | Buy |
| 2022-12-06 | Eingeleitet | Cowen | Outperform |
| 2022-10-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-21 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-02-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2020-02-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-01-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-08-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-04-12 | Eingeleitet | Guggenheim | Buy |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Neutral |
| 2017-03-02 | Bestätigt | Wedbush | Outperform |
| 2016-10-04 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-12-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-08-05 | Bestätigt | MLV & Co | Buy |
| 2015-02-12 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-28 | Bestätigt | MLV & Co | Buy |
| 2014-07-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Xencor Inc Aktie (XNCR) Neueste Nachrichten
Xencor, Inc. (NASDAQ:XNCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - uk.finance.yahoo.com
Xencor price target lowered to $26 from $31 at Wedbush - Yahoo Finance
Xencor’s XmAb541 Study Completion: A Potential Game-Changer in Oncology - TipRanks
Xencor’s XmAb808 Study: A New Frontier in Cancer Treatment - TipRanks
Xencor’s XmAb541 Study: A Promising Step in Cancer Treatment - TipRanks
Xencor’s XmAb942 Shows Promising Efficacy and Strategic Advancements, Earning a Buy Rating - TipRanks
Wedbush Cuts Price Target on Xencor to $26 From $31, Keeps Outperform Rating - MarketScreener
Xencor’s Strategic Advances and Promising Pipeline Drive Buy Rating - TipRanks
Xencor 2025 Q2 Earnings Strong Revenue Growth, 55.2% Reduction in Net Loss - AInvest
Xencor Reports Second Quarter 2025 Financial Results - BioSpace
Xencor, Inc. Reports Revenue Growth Amidst Continued Losses - TipRanks
Xencor Inc earnings beat by $0.31, revenue topped estimates - Investing.com Australia
Xencor: Q2 Earnings Snapshot - San Antonio Express-News
Xencor Q2 Earnings: Losses Reported but Revenue Surpasses ExpectationsNews and Statistics - IndexBox
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Xencor (XNCR) Q2 Revenue Jumps 82% - sharewise.com
Xencor, Inc.'s (NASDAQ:XNCR) Price Is Right But Growth Is Lacking - simplywall.st
Xencor Inc. Flashes Rebound Signal in Oversold ConditionConfirmed Setup With Expert Accuracy Supported - metal.it
How does Xencor Inc. generate profit in a changing economyRapid market gains - Jammu Links News
What is the dividend policy of Xencor Inc. stockMaximize portfolio value with expert tips - Jammu Links News
When is Xencor Inc. stock expected to show significant growthSuperior capital gains - Jammu Links News
What is Xencor Inc. company’s growth strategyLightning-fast growth - Jammu Links News
Is it the right time to buy Xencor Inc. stockSky-high return potential - Jammu Links News
How many analysts rate Xencor Inc. as a “Buy”Overwhelming profit margins - Jammu Links News
What catalysts could drive Xencor Inc. stock higher in 2025Strong return on investment - Jammu Links News
How does Xencor Inc. compare to its industry peersConsistent triple returns - Jammu Links News
Should I hold or sell Xencor Inc. stock in 2025Triple-digit growth rates - Jammu Links News
Is Xencor Inc. a growth stock or a value stockFree Expert Stock Watchlist - Jammu Links News
Is Xencor Inc. a good long term investmentCapitalize on market momentum for big wins - Jammu Links News
Xencor Appoints Raymond Deshaies to Board of Directors to Bolster Drug Development Efforts - AInvest
How volatile is Xencor Inc. stock compared to the marketJaw-dropping returns - Jammu Links News
Xencor XNCR 2025Q2 Earnings Preview Upside Potential on Robust Revenue Growth - AInvest
Pasadena-Based Biopharmaceutical Firm Xencor Names Veteran Scientist to Board - Pasadena Now
Xencor appoints biotech veteran Raymond Deshaies to board of directors By Investing.com - Investing.com India
Xencor Appoints Raymond Deshaies to Board of Directors - TipRanks
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors - FinancialContent
Xencor’s XmAb819 Study: A Promising Step in Renal Cell Carcinoma Treatment - TipRanks
RSI Reset May Fuel Rebound in Xencor Inc.AI Based High Gain Watchlist Scanner Shared - metal.it
Why Xencor Inc. stock attracts strong analyst attentionTechnical Stock Breakout Predictions Signal Entry Points - metal.it
What is the risk reward ratio of investing in Xencor Inc. stockPowerful profit generation - jammulinksnews.com
Will Xencor Inc. Reverse From Oversold ConditionsROI Driven Equity Selection With Safety Emphasized - beatles.ru
Moving Average Trends for Xencor Inc. Stock: What They IndicateAnalyst Grade Signals - Newser
Price action breakdown for Xencor Inc.Free Early Breakout Entry Point Notifications - Newser
Finanzdaten der Xencor Inc-Aktie (XNCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):